Bioasis Announces Filing of Its Fourth Quarter and Fiscal Year-End Financial Statements and MD&A
June 26 2018 - 8:22PM
Business Wire
BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF;
TSX.V:BTI), a biopharmaceutical company developing its xB3 TM
proprietary platform technology for the delivery of therapeutics
across the blood-brain barrier (BBB) and the treatment of CNS
disorders in areas of high unmet medical need, including brain
cancers and neurodegenerative diseases, today announced that it has
filed its fourth quarter and annual audited consolidated financial
statements and management’s discussion and analysis for the
years ended February 28, 2018 and February 28, 2017. All are
available under the Company's profile on SEDAR
at www.sedar.com and on the Company's website
at www.bioasis.us/investors/.
On behalf of the Board of Directors of Bioasis Technologies
Inc.
Mark Day, Ph.D., President and Chief Executive Officer
About Bioasis
Bioasis Technologies Inc. is a biopharmaceutical company
developing xB3, a proprietary platform technology for the delivery
of therapeutics across the blood-brain barrier (BBB) and the
treatment of CNS disorders in areas of high unmet medical need,
including brain cancers and neurodegenerative diseases. The
delivery of therapeutics across the BBB represents the final
frontier in treating neurological disorders. The in-house
development programs at Bioasis are designed to develop symptomatic
and disease-modifying treatments for brain-related diseases and
disorders. The company maintains headquarters in Richmond, BC,
Canada with offices in Guilford, Conn., United States. Bioasis
trades on the TSX Venture Exchange under the symbol “BTI” and on
the OTCQB under the symbol “BIOAF.” For more information about the
company please visit www.bioasis.ca
or www.bioasis.us.
“Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.”
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180626006652/en/
Media & Investor Relations:Catherine London,
+1-917-763-2709Catherine@bioasis.us
BiOasis Technologies (TSXV:BTI)
Historical Stock Chart
From Aug 2024 to Sep 2024
BiOasis Technologies (TSXV:BTI)
Historical Stock Chart
From Sep 2023 to Sep 2024